Navient (NAVI) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +61.11%. A quarter ago, it was expected that this student loan servicing company would post earnings of $0.27 per share when it actually produced earnings of $0.21, delivering a surprise of -22.22%.Over the last four quart ...

Kadant (KAI) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.18 per share. This compares to earnings of $2.84 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +18.81%. A quarter ago, it was expected that this equipment supplier for the papermaking and paper recycling industries would post earnings of $1.94 per share when it actually produced earnings of $2.31, delivering a surpris ...

Expand Energy (EXE) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +10.23%. A quarter ago, it was expected that this oil and gas company would post earnings of $1.14 per share when it actually produced earnings of $1.1, delivering a surprise of -3.51%.Over the last four quarters, the ...

2025年第三季度业绩表现 - 调整后每股收益为3美元 超出Zacks共识预期1.4% 同比增长5.6% [1] - 总营收达41亿美元 略超共识预期 同比增长5.2% [1] - 调整后税息折旧及摊销前利润为9.49亿美元 同比增长1.1% 超出公司预期 [4] 各业务部门收入情况 - 研发部门收入23亿美元 同比增长4.5% 按固定汇率计算增长3.4% 超出公司22亿美元的预期 [3] - 技术与分析部门收入16亿美元 同比增长5% 按固定汇率计算增长3.3% 未达到公司17亿美元的预期 [3] - 合同销售与医疗解决方案收入2.09亿美元 同比增长16.1% 按固定汇率计算增长13.9% 超出公司1.817亿美元的预期 [4] 财务状况与现金流 - 季度末现金及现金等价物为18亿美元 上一季度为20亿美元 [5] - 长期债务（扣除流动部分）为150亿美元 第二季度末为154亿美元 [5] - 经营活动产生的净现金为9.08亿美元 资本支出为1.36亿美元 季度自由现金流达7.72亿美元 [5] 2025年全年业绩指引 - 更新营收指引至161.5亿-162.5亿美元 中点162亿美元高于Zacks共识预期161.6亿美元 [6] - 更新每股收益指引至11.85-11.95美元 中点11.90美元高于共识预期11.86美元 [6] - 调整后税息折旧及摊销前利润指引更新为37.75亿-38.00亿美元 [7] 股价表现 - 过去六个月股价上涨44.9% 表现优于行业13.2%的增长率及Zacks标普500综合指数26.6%的涨幅 [2] 其他公司业绩摘要 - Waste Connections第三季度调整后每股收益1.44美元 超出共识预期4.4% 同比增长6.7% 营收25亿美元同比增长5.1% [8][10] - Equifax第三季度调整后每股收益2.04美元 超出共识预期5.7% 同比增长10.3% 营收15亿美元同比增长6.9% [11]

核心财务业绩 - 第一季度调整后每股收益为1.15美元，同比增长5.5%，超出市场普遍预期的1.12美元 [1] - 季度销售额为211.48亿美元，同比增长3.2%，超出市场预期的210.8亿美元 [1] - 毛利润增长3.9%至39亿美元，毛利率扩大13个基点至18.5% [3][6] 分部运营表现 - 美国食品服务业务销售额增长2.9%至148亿美元，总案例量微增0.1%，本地案例量下降0.2% [4] - 国际食品服务业务销售额增长4.5%至40亿美元，该部门实现了有效的利润率管理、本地销量增长和两位数的利润增长 [5] - 宽线本地业务在本季度表现积极，且在整个季度内逐期改善 [2] 盈利能力与现金流 - 调整后营业收入增长2.9%至8.98亿美元，调整后营业利润率为4.3% [6] - 调整后息税折旧摊销前利润微增0.1%至11亿美元 [6] - 运营现金流为8600万美元，自由现金流为负5000万美元 [7] 财务状况与展望 - 季度末公司持有现金余额8.44亿美元，总流动性为35亿美元 [7] - 公司重申2026财年调整后每股收益指引为4.50至4.60美元，市场共识为4.59美元 [8] - 维持2026财年销售额指引为840亿至850亿美元，市场预期为845.36亿美元 [8]

Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +160.00%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.13, delivering a surprise of +27.78%.Over the last four qu ...

Alkermes (ALKS) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +16.67%. A quarter ago, it was expected that this drugmaker would post earnings of $0.41 per share when it actually produced earnings of $0.52, delivering a surprise of +26.83%.Over the last four quarters, the company has ...

Regeneron (REGN) came out with quarterly earnings of $11.83 per share, beating the Zacks Consensus Estimate of $9.44 per share. This compares to earnings of $12.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +25.32%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $8.03 per share when it actually produced earnings of $12.89, delivering a surprise of +60.52%.Over the last four quart ...

财务业绩展望 - 公司预期截至2025年9月30日止6个月将取得不超过50万港元的净利润 [1] - 相比去年同期截至2024年9月30日止6个月的净亏损约1700万港元，业绩实现转亏为盈 [1] 业绩改善原因 - 业绩改善主要由于向投资对象提供的贷款减值亏损减少 [1] - 员工成本及其他经营开支减少亦为原因之一 [1] - 去年同期出售经营亏损的附属公司对本次业绩同比改善有积极影响 [1]

核心业绩表现 - 公司最新季度每股收益为3.11美元，与市场预期一致，但低于去年同期3.45美元的水平 [1] - 最新季度营收为31.7亿美元，超出市场预期0.60%，但低于去年同期的32.5亿美元 [2] - 在过去四个季度中，公司有三次每股收益超出预期，四次营收超出预期 [1][2] 历史业绩与市场表现 - 上一季度公司每股收益为2.72美元，超出预期2.66美元，带来2.26%的正向惊喜 [1] - 公司股价年初至今上涨约5.4%，表现逊于标普500指数15.5%的涨幅 [3] 未来业绩展望 - 当前市场对下一季度的共识预期为每股收益3.23美元，营收32.1亿美元 [7] - 对本财年的共识预期为每股收益11.71美元，营收121.2亿美元 [7] - 在本次财报发布前，公司的盈利预期修正趋势向好，目前Zacks评级为第2级（买入） [6] 行业比较与前景 - 公司所属的半导体-模拟与混合行业在Zacks行业排名中位列前14% [8] - 研究显示排名前50%的行业表现优于后50%的行业，优势超过2比1 [8] - 同业公司微芯科技预计在即将发布的报告中公布季度每股收益0.33美元，同比下跌28.3% [9] - 微芯科技预计季度营收为11.3亿美元，同比下降2.7%，且其每股收益预期在过去30天内被下调0.4% [9][10]